XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Commitments and Contingencies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract] |
Schedule of Contractual Clinical Trials | The following is a summary of the Company’s ongoing contractual clinical trials described below as of June 30, 2024: Schedule of Contractual Clinical Trials
Description of Clinical Trial |  | Institution |  | Start Date |  | Projected End Date |  | Number of Patients in Trial |  |  | Study Objective |  | Clinical Update |  | Expected Date of Preliminary Efficacy Signal |  | NCT No. |  | Remaining Financial Contractual Commitment |
LB-100 combined with atezolizumab in microsatellite stable metastatic colon cancer (Phase 1b) |  | Netherlands Cancer Institute (NKI) |  | September 2024 |  | December 2026 |  |  | 37 |  |  | Determine RP2D with atezolizumab |  | Trial planned to open to accrual in 3rd quarter 2024 |  | June 2026 |  | NCT06012734 |  |  | - | (1)
LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b) |  | GEIS |  | June 2023 |  | Recruitment completed June 2024 |  |  | 9 to 18 |  |  | Determine MTD and RP2D |  | Twelve patients entered |  | December 2024 |  | NCT05809830 |  | $ | 267,000 |
Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2) |  | GEIS |  | TBD |  | TBD |  |  | 150 |  |  | Determine efficacy: PFS |  | Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial) |  | December 2026 |  | NCT05809830 |  | $ | 3,200,000 |
LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2) |  | MD Anderson |  | January 2024 |  | December 2027 |  |  | 21 |  |  | Determine the OS of patients with ovarian clear cell carcinoma |  | Three patients entered |  | December 2026 |  | NCT06065462 |  |  | - | (1)
Total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 3,467,000 |
(1) | The Company has no financial contractual commitment associated with this clinical trial at June 30, 2024.

X
- Definition Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Subparagraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration